Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Stivarga | Regorafenib | Unresectable Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Stivarga (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Stivarga (GIST) | Regorafenib | Gastrointestinal Stromal Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Stivarga Resubmission (CRC) | Regorafenib | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Veklury | remdesivir | COVID-19 in hospitalized patients | Active | |||
| Veklury | remdesivir | COVID-19 in non-hospitalized patients | Active | |||
| Cinqair | Reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cinqair | reslizumab | Asthma, eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 11, 2024